Molecular targeted therapies in hepatocellular carcinoma

The Hallmarks of Cancer

2000 • 27,569 citations

Global Cancer Statistics, 2002

2005 • 17,966 citations

Sorafenib in Advanced Hepatocellular Carcinoma

2008 • 11,718 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Management of hepatocellular carcinoma

2005 • 5,799 citations

Sorafenib in Advanced Hepatocellular Carcinoma

2008 • 5,675 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 • 5,572 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

2005 • 5,199 citations

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

2006 • 4,800 citations

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 • 4,669 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

2013 • 4,369 citations

Cancer genes and the pathways they control

2004 • 4,172 citations

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 • 3,560 citations

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 • 3,283 citations

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

2007 • 3,010 citations

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

2003 • 2,945 citations

Rising Incidence of Hepatocellular Carcinoma in the United States

1999 • 2,875 citations

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

2005 • 2,842 citations

Protein kinases — the major drug targets of the twenty-first century?

2002 • 2,101 citations

Hepatocellular carcinoma pathogenesis: from genes to environment

2006 • 1,940 citations

WNT and β-catenin signalling: diseases and therapies

2004 • 1,703 citations

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 • 1,693 citations

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

2008 • 1,618 citations

Cetuximab in the treatment of colorectal cancer.

2004 • 1,501 citations

Insulin-like growth factors and neoplasia

2004 • 1,452 citations

Molecular pathogenesis of human hepatocellular carcinoma

2002 • 1,424 citations

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

2005 • 1,418 citations

mTOR and cancer: insights into a complex relationship

2006 • 1,299 citations

Liver Regeneration

2006 • 1,282 citations

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

2006 • 1,186 citations

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

2006 • 1,129 citations

The protein tyrosine kinase family of the human genome

2000 • 1,107 citations

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells

2006 • 911 citations

Resection and Liver Transplantation for Hepatocellular Carcinoma

2005 • 875 citations

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment

2006 • 811 citations

Drug development of MET inhibitors: targeting oncogene addiction and expedience

2008 • 800 citations

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

2005 • 724 citations

Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC

2006 • 673 citations

Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

2008 • 633 citations

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

2007 • 581 citations

Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis

2001 • 567 citations

Focus on hepatocellular carcinoma

2004 • 561 citations

Genomics and Signaling Pathways in Hepatocellular Carcinoma

2007 • 555 citations

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

2005 • 466 citations

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

2004 • 461 citations

Hepatocellular Carcinoma: Epidemiology, Risk Factors, and Screening

2005 • 401 citations

Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

2006 • 393 citations

Dysregulation of growth factor signaling in human hepatocellular carcinoma

2006 • 387 citations

Strategies for optimizing combinations of molecularly targeted anticancer agents

2006 • 350 citations

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

2006 • 350 citations

Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma

2009 • 340 citations

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

2005 • 321 citations

To kill a tumor cell: the potential of proapoptotic receptor agonists

2008 • 312 citations

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

2007 • 294 citations

Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets

2005 • 282 citations

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

2007 • 247 citations

Medicare and Cost-Effectiveness Analysis

2005 • 232 citations

Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers

2003 • 229 citations

Experimental models of hepatocellular carcinoma

2008 • 216 citations

Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy

2006 • 163 citations

Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma.

2003 • 153 citations

Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression

2004 • 130 citations

Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma

2006 • 115 citations

Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203

2006 • 109 citations

Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis

2007 • 102 citations

A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

2007 • 77 citations

Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study

2007 • 74 citations

Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

2007 • 74 citations

Rethinking clinical trials for cytostatic drugs

2003 • 72 citations

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps

2008 • 69 citations

Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring

2007 • 69 citations

The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)

2007 • 62 citations

3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

2007 • 56 citations

A phase II study of sunitinib in patients with advanced hepatocellular carcinoma

2007 • 56 citations

Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein

2006 • 56 citations

Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study

2008 • 26 citations

Lipid rafts remodeling in estrogen receptor–negative breast cancer is reversed by histone deacetylase inhibitor

2006 • 26 citations